MediWound (NASDAQ:MDWD) Rating Reiterated by HC Wainwright

MediWound (NASDAQ:MDWD – Get Rating)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Friday, Benzinga reports. They currently have a $23.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 110.43% from the stock’s current price.

Several other analysts have also weighed in on MDWD. Cowen increased their price target on MediWound from $6.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, December 30th. Maxim Group started coverage on MediWound in a report on Thursday, December 22nd. They set a “buy” rating on the stock. Finally, StockNews.com assumed coverage on MediWound in a report on Thursday. They set a “hold” rating on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.40.

MediWound Stock Performance

NASDAQ:MDWD opened at $10.93 on Friday. The stock’s fifty day moving average is $12.69 and its 200 day moving average is $11.47. MediWound has a fifty-two week low of $8.05 and a fifty-two week high of $17.08. The firm has a market capitalization of $63.61 million, a PE ratio of -2.95 and a beta of 0.98.

Institutional Trading of MediWound

A number of hedge funds and other institutional investors have recently bought and sold shares of MDWD. PNC Financial Services Group Inc. purchased a new position in shares of MediWound during the fourth quarter valued at $57,000. Essex Investment Management Co. LLC purchased a new position in shares of MediWound during the third quarter valued at $405,000. Sargent Investment Group LLC increased its stake in shares of MediWound by 7.2% during the third quarter. Sargent Investment Group LLC now owns 562,350 shares of the biopharmaceutical company’s stock valued at $799,000 after buying an additional 37,600 shares during the period. Renaissance Technologies LLC increased its stake in shares of MediWound by 3.8% during the second quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after buying an additional 17,600 shares during the period. Finally, Altium Capital Management LP purchased a new position in shares of MediWound during the third quarter valued at $1,775,000. Hedge funds and other institutional investors own 13.58% of the company’s stock.

About MediWound

(Get Rating)

MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.